Dr Monk on Avutometinib Plus Defactinib in Low-Grade Serous Ovarian Cancer

Bradley Monk, MD, FACS, FACOG, discusses findings from the phase 2 RAMP 201 trial in patients with low-grade serous ovarian cancer and the importance of these results within the context of the larger ovarian cancer treatment paradigm. 

Related Keywords

Arizona ,United States ,University Of Arizona , ,Division Of Gynecologic Oncology ,University Of Arizona College Medicine ,Us Oncology Research Network ,Arizona Oncology Us Network ,Creighton University School Of Medicine At St ,Gynecologic Program ,Bradley Monk ,Gynecologic Oncology ,Arizona Oncology ,Arizona College ,Creighton University School ,Research Network ,D ,Pacs ,Iacog ,Ramp 201 Trial ,Patients With Low Grade Serous Ovarian Cancer ,Us Oncology Network ,Creighton University School Of Medicine At St Josephs Hospital ,The Gog Foundation ,Gog Partners ,Nct04625270 ,Avutometinib Plus Defactinib ,